Cigarette Smoking Clinical Trial
Official title:
Smoking Topography and Harm Exposure in a New Potentially Reduced Exposure Product
The proposed research extends previous research on Quest® cigarette smoking behavior by testing whether compensatory smoking occurs as cigarette nicotine level decreases, and whether, as a result, biomarkers of harm exposure increase. This hypothesis will be tested in 210 smokers who report smoking at least 15 cigarettes per day and have been smoking for at least five years and are not currently interested in quitting, but interested in trying a new cigarette product. Participants will be randomized to one of three conditions: 1) smoke their own preferred brand (control group); 2) smoke Quest® cigarettes in progressively decreasing cigarette nicotine level (step-down); or 3) Quest® cigarette non-step-down condition, where they will smoke Quest® cigarettes in a random order. The study will consist of 4 stages beginning with a 5-day preferred own brand cigarette smoking phase for all participants, followed by one of the three cigarette conditions. For those smoking Quest® cigarettes, cigarette nicotine level will change every 10 days, either in a step-down or random fashion. The primary behavioral outcome is smoking topography, a quantitative measurement of smoke exposure. Alveolar carbon monoxide (CO), a validated assessment of smoke exposure, and urine samples to assess carcinogen exposure, specifically NNAL (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol) and 1-HOP (1-hydroxypyrere), and exhaled breath condensate will also be collected at the laboratory visits. At the initiation of the study, participants will view the Quest® print advertisement and complete a survey related to product expectations in order to determine the impact marketing and advertisement has on beliefs, attitudes and behaviors related to Quest® cigarettes.
n/a
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04043728 -
Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study
|
N/A | |
Completed |
NCT04284813 -
Families With Substance Use and Psychosis: A Pilot Study
|
N/A | |
Active, not recruiting |
NCT02643914 -
Control Systems Approach to Predicting Individualized Dynamics of Nicotine Cravings
|
N/A | |
Recruiting |
NCT02422914 -
Benefits of Tobacco Free Cigarette
|
N/A | |
Active, not recruiting |
NCT02629679 -
Sports, Education and Consumption of Substances in Adolescents
|
N/A | |
Completed |
NCT02385227 -
Characterization of Biomarkers of Tobacco Exposure, Urge-to-Smoke Following Exclusive and Dual Ad Lib Use of Electronic Cigarettes
|
N/A | |
Completed |
NCT02218281 -
Developing a Smartphone App With Mindfulness Training for Teen Smoking Cessation
|
N/A | |
Completed |
NCT01199380 -
Behavioral Activation Intervention for Smoking Cessation in Smokers With Depressive Symptoms
|
Phase 2 | |
Completed |
NCT00756704 -
The Effectiveness of Smoking Cessation Guidelines in the Emergency Department
|
N/A | |
Completed |
NCT00802919 -
Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors
|
Phase 4 | |
Completed |
NCT01081119 -
Brief Voluntary Alcohol and Drug Intervention for Middle School Youth
|
Phase 2 | |
Completed |
NCT01692353 -
Cardiovascular Disease Biomarkers in Smokers and Moist Snuff Consumers
|
N/A | |
Completed |
NCT00682474 -
School Nurse-Delivered Smoking Cessation Intervention
|
Phase 2/Phase 3 | |
Completed |
NCT05520775 -
Semaglutide for Alcohol Use Disorder
|
Phase 2 | |
Completed |
NCT03743532 -
E-Cigarettes and Financial Incentives to Promote Tobacco Harm Reduction Among Adults Accessing Shelter Services
|
N/A | |
Terminated |
NCT03840694 -
Nicotine Withdrawal and Reward Processing: Connecting Neurobiology to Real-world Behavior
|
N/A | |
Completed |
NCT06032793 -
Effects of Deep Breathing Exercise on Pulmonary Function, Perceived Stress and Physical Fitness.
|
N/A | |
Terminated |
NCT03326128 -
High Dose Bupropion for Smoking Cessation - Pilot Study
|
Phase 2 | |
Recruiting |
NCT03218670 -
Your Health in On Click
|
N/A | |
Completed |
NCT02538042 -
Strengthening Instrumental Extinction to Prevent Smoking Relapse (VLNCCue)
|
N/A |